子宫癌肉瘤中TROP2的表达及治疗靶向研究
在72例子宫癌肉瘤(UCS)存档组织中检测TROP2蛋白和mRNA表达,并建立9例UCS类器官(PDO)和2例人源肿瘤异种移植(PDX)模型评估TROP2抗体药物偶联物戈沙妥珠单抗(SG)的疗效。结果显示≥90%原发UCS可检出TROP2表达,所有PDO对SG呈剂量依赖性反应,中位IC50为167.7 pM,两例PDX模型经SG治疗后肿瘤体积均显著缩小;作者认为需进一步研究TROP2靶向治疗。
要点
- ≥90%的原发子宫癌肉瘤可检出TROP2蛋白和mRNA表达。
- 9例UCS类器官均对SG呈剂量依赖性反应,中位IC50为167.7 pM(范围51.4 pM-3.2 nM)。
- 高、低TROP2蛋白表达的两例PDX模型经SG治疗后肿瘤体积均显著缩小(p=0.03和p=0.02)。
核心结论
- 大多数子宫癌肉瘤可检出TROP2表达。
- SG在UCS类器官和PDX模型中的反应结果提示需进一步研究TROP2靶向治疗用于这一侵袭性疾病患者。
研究设计与样本
- 在72例子宫癌肉瘤存档组织中采用免疫组化检测TROP2蛋白、qRT-PCR检测mRNA表达。
- 建立9例UCS类器官模型并进行panel测序分子表征,测定TROP2水平。
- 在UCS类器官和2例PDX模型中评估TROP2抗体药物偶联物戈沙妥珠单抗(SG)的疗效。
主要发现
- TROP2蛋白和mRNA在≥90%的原发UCS中可检出。
- 以癌成分占优势或同源性分化的UCS,TROP2表达高于以肉瘤成分占优势或异源性分化者(p<0.001和p=0.022)。
- UCS类器官显示TROP2表达,其分子谱可反映各自原发UCS(原发UCS中存在的突变在PDO中的中位比例为88%,范围50-100%)。
- 全部9例UCS类器官对SG呈剂量依赖性反应,中位IC50为167.7 pM(范围51.4 pM-3.2 nM)。
- 高和低TROP2蛋白表达的两例UCS PDX模型经SG治疗后肿瘤体积均显著缩小(p=0.03和p=0.02)。
局限性
- 作者指出其研究结果需进一步研究TROP2靶向治疗用于这一侵袭性疾病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare and aggressive type of endometrial carcinoma (EC), and novel therapeutic strategies are needed. We sought to assess TROP2 expression in archival UCSs and TROP2 antibody-drug conjugate (ADC) targeting in patient-derived UCS organoid (PDO) and xenograft (PDX) models. METHODS: TROP2 protein (immunohistochemistry) and mRNA (qRT-PCR) expression were assessed in 72 archival UCS tissues. Nine UCS PDO models were established and molecularly characterized by panel sequencing; then, TROP2 levels were determined and the efficacy of the TROP2 ADC sacituzumab govitecan (SG) defined in the UCS PDO and PDX models (n = 2). RESULTS: TROP2 protein and mRNA expression were detected in ≥90 % of primary UCSs, and those with a predominant carcinomatous component or with homologous differentiation had higher TROP2 expression than those with a predominant sarcomatous component or with heterologous differentiation (p < 0.001 and p = 0.022, respectively). UCS PDOs displayed TROP2 expression and molecular profiles (median 88 %, range 50-100 % of mutation in primary UCSs present in PDOs) reflective of their respective primary UCSs. All 9 UCS PDOs responded in a dose-dependent manner to SG treatment, with a median IC50 of 167.7pM (range 51.4pM-3.2 nM). In addition, both UCS PDX models with high and low TROP2 protein expression had a significant reduction in tumor volume with SG treatment (p = 0.03 and p = 0.02, respectively). CONCLUSIONS: We demonstrate that the majority of UCSs have detectable TROP2 expression. Our findings on the SG response in UCS PDO and PDX models warrant further studies on TROP2 targeting for patients with this aggressive disease.
引用
- Moufarrij S, Dopeso H, Brown DN, et al. TROP2 expression and therapeutic targeting in uterine carcinosarcoma. Gynecol Oncol. 2025. PMID: 40344963. doi:10.1016/j.ygyno.2025.04.590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。